{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:42:56Z","timestamp":1791308576611,"version":"4.3.1"},"reference-count":64,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Projects of Shanghai Municipal Science and Technology Commission","award":["18411968700"],"award-info":[{"award-number":["18411968700"]}]},{"DOI":"10.13039\/501100020771","name":"Young Scientists Fund of the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81200628"],"award-info":[{"award-number":["81200628"]}],"id":[{"id":"10.13039\/501100020771","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation Project of Shanghai","award":["12ZR1417800"],"award-info":[{"award-number":["12ZR1417800"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Up to 40% of patients with polycystic ovary syndrome (PCOS) have prediabetes; an optimal pharmacotherapy regimen for diabetes prevention in PCOS is yet to be established.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Randomized, open-label, parallel-group controlled trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>PCOS with prediabetes (fasting plasma glucose 5.6-6.9 mmol\/L and\/or 2 hour post glucose 7.8-11.0 mmol\/L on oral glucose tolerance test [OGTT]). A total of 150 out of 183 eligible enrollees completed the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>EX (10-20\u03bcg daily), MET (1500-2000 mg daily), or COM (EX plus MET) for 12 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Sustained remission rate of prediabetes (primary endpoint, a normal OGTT after 12 weeks of treatment followed by 12 weeks of washout on no drug treatment) along with anthropometric, hormonal, metabolic, and pancreatic \u03b2-cell function parameters (secondary endpoints) and potential mechanisms were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Impaired glucose tolerance was found the dominant prediabetes phenotype. Overall sustained prediabetes remission rate was 50.7%. Remission rate of COM group (64%, 32\/50) or EX group (56%, 28\/50) was significantly higher than that of the MET group (32%, 16\/50) (P\u2005=\u2005.003 and .027, respectively). EX was associated with superior suppression of 2-hour glucose increment in OGTT. A 2-step hyperglycemic clamp study revealed that EX had led to higher postprandial insulin secretion than MET, potentially explaining the higher remission rate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Compared with MET monotherapy, EX or COM achieved higher rate of remission of prediabetes among PCOS patients by improving postprandial insulin secretion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa692","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:09:09Z","timestamp":1601424549000},"page":"e1420-e1432","source":"Crossref","is-referenced-by-count":55,"title":["Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-9352","authenticated-orcid":false,"given":"Tao","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-5339","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Rong","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ning","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Sun","sequence":"additional","affiliation":[{"name":"Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Center for Reproductive Medicine, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WuQiang","family":"Fan","sequence":"additional","affiliation":[{"name":"Diabetes Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"},{"name":"Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Center for Reproductive Medicine, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"9588","key":"2021122117213756900_CIT0001","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(07)61345-2","article-title":"Polycystic ovary syndrome","volume":"370","author":"Norman","year":"2007","journal-title":"Lancet."},{"issue":"6","key":"2021122117213756900_CIT0002","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev."},{"issue":"1","key":"2021122117213756900_CIT0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.fertnstert.2016.09.023","article-title":"Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin\/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study","volume":"107","author":"Elkind-Hirsch","year":"2017","journal-title":"Fertil Steril."},{"key":"2021122117213756900_CIT0004","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes A.","year":"2020","journal-title":"Diabetes Care."},{"issue":"7","key":"2021122117213756900_CIT0005","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ijo.2008.61","article-title":"Polycystic ovary syndrome in adolescents","volume":"32","author":"Franks","year":"2008","journal-title":"Int J Obes (Lond)."},{"issue":"3","key":"2021122117213756900_CIT0006","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2337\/dc07-9920","article-title":"Impaired fasting glucose and impaired glucose tolerance: implications for care","volume":"30","author":"Nathan","year":"2007","journal-title":"Diabetes Care."},{"issue":"6","key":"2021122117213756900_CIT0007","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","article-title":"Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study","volume":"7","author":"Gong","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2021122117213756900_CIT0008","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/AOG.0b013e31822c887f","article-title":"Continuous glucose monitoring during pregnancy in women with polycystic ovary syndrome","volume":"118","author":"Dmitrovic","year":"2011","journal-title":"Obstet Gynecol."},{"key":"2021122117213756900_CIT0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2840-2-9","article-title":"Silent myocardial infarction in women with impaired glucose tolerance: the Northern Sweden MONICA study","volume":"2","author":"Lundblad","year":"2003","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"2021122117213756900_CIT0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.numecd.2008.02.002","article-title":"Association between impaired glucose tolerance and carotid atherosclerosis: a study in 64-year-old women and a meta-analysis","volume":"19","author":"Brohall","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"6","key":"2021122117213756900_CIT0011","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1210\/jc.2004-1843","article-title":"Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study","volume":"90","author":"Legro","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122117213756900_CIT0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med."},{"issue":"10","key":"2021122117213756900_CIT0013","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","article-title":"Therapeutic use of metformin in prediabetes and diabetes prevention","volume":"75","author":"Hostalek","year":"2015","journal-title":"Drugs."},{"issue":"8","key":"2021122117213756900_CIT0014","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/dom.12270","article-title":"Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies","volume":"16","author":"Merlotti","year":"2014","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"2021122117213756900_CIT0015","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122117213756900_CIT0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/humrep\/der396","article-title":"Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS)","volume":"27","author":"Amsterdam EA-SrPCWG","year":"2012","journal-title":"Hum Reprod."},{"issue":"3","key":"2021122117213756900_CIT0017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12522-013-0145-1","article-title":"Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan","volume":"12","author":"Kubota","year":"2013","journal-title":"Reprod Med Biol."},{"issue":"1","key":"2021122117213756900_CIT0018","first-page":"2","article-title":"[Chinese guideline for diagnosis and management of polycystic ovary syndrome]","volume":"53","author":"Endocrinology Subgroup and Expert Panel Chines Society of Obstetrics and Gynecology, Chinese Medical Association","year":"2018","journal-title":"Zhonghua Fu Chan Ke Za Zhi."},{"issue":"9","key":"2021122117213756900_CIT0019","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum Reprod."},{"issue":"3","key":"2021122117213756900_CIT0020","first-page":"942","article-title":"Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome","volume":"81","author":"Dunaif","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122117213756900_CIT0021","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1172\/JCI118064","article-title":"Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus","volume":"96","author":"Ehrmann","year":"1995","journal-title":"J Clin Invest."},{"issue":"6","key":"2021122117213756900_CIT0022","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.fertnstert.2016.02.004","article-title":"Distinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndrome","volume":"105","author":"Kim","year":"2016","journal-title":"Fertil Steril."},{"issue":"8","key":"2021122117213756900_CIT0023","first-page":"777","article-title":"Early impaired \u03b2-cell function in Chinese women with polycystic ovary syndrome","volume":"5","author":"Tao","year":"2012","journal-title":"Int J Clin Exp Pathol."},{"issue":"10","key":"2021122117213756900_CIT0024","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat Rev Endocrinol."},{"issue":"10","key":"2021122117213756900_CIT0025","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s40265-015-0420-z","article-title":"Exenatide extended-release: an updated review of its use in Type 2 diabetes mellitus","volume":"75","author":"Syed","year":"2015","journal-title":"Drugs."},{"issue":"9","key":"2021122117213756900_CIT0026","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrd1828","article-title":"Exenatide","volume":"4","author":"Davidson","year":"2005","journal-title":"Nat Rev Drug Discov."},{"issue":"12","key":"2021122117213756900_CIT0027","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1464-5491.2012.03699.x","article-title":"Exenatide plus metformin compared with metformin alone on \u03b2-cell function in patients with Type 2 diabetes","volume":"29","author":"Derosa","year":"2012","journal-title":"Diabet Med."},{"issue":"1","key":"2021122117213756900_CIT0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.diabres.2012.05.022","article-title":"Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, \u03b2-cell function and insulin resistance in type 2 diabetic patients","volume":"98","author":"Derosa","year":"2012","journal-title":"Diabetes Res Clin Pract."},{"issue":"8","key":"2021122117213756900_CIT0029","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/phar.1301","article-title":"Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial","volume":"33","author":"Derosa","year":"2013","journal-title":"Pharmacotherapy."},{"issue":"9","key":"2021122117213756900_CIT0030","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1139\/cjpp-2012-0300","article-title":"Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy","volume":"91","author":"Derosa","year":"2013","journal-title":"Can J Physiol Pharmacol."},{"issue":"1","key":"2021122117213756900_CIT0031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"Rotterdam EA-SPcwg.","year":"2004","journal-title":"Hum Reprod."},{"key":"2021122117213756900_CIT0032","volume-title":"The Asia-Pacific Perspective: Redefining Obesity and its Treatment.","author":"WHO Regional Office for the Western Pacific.","year":"2000"},{"key":"2021122117213756900_CIT0033","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1476-511X-10-183","article-title":"Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population","volume":"10","author":"Amato","year":"2011","journal-title":"Lipids Health Dis."},{"issue":"2","key":"2021122117213756900_CIT0034","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1210\/jc.2003-031287","article-title":"Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry","volume":"89","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122117213756900_CIT0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0015-0282(16)45254-4","article-title":"Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females","volume":"35","author":"Mathur","year":"1981","journal-title":"Fertil Steril."},{"issue":"7","key":"2021122117213756900_CIT0036","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia."},{"issue":"9","key":"2021122117213756900_CIT0037","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care."},{"issue":"12","key":"2021122117213756900_CIT0038","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s001250051561","article-title":"Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test","volume":"43","author":"Albareda","year":"2000","journal-title":"Diabetologia."},{"issue":"2","key":"2021122117213756900_CIT0039","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/1753-0407.12175","article-title":"Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on \u03b2-cell function in a newly designed two-step hyperglycemic clamp","volume":"7","author":"Zhang","year":"2015","journal-title":"J Diabetes."},{"issue":"10120","key":"2021122117213756900_CIT0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet."},{"issue":"3","key":"2021122117213756900_CIT0041","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4158\/EP11194.OR","article-title":"Successful treatment of prediabetes in clinical practice: targeting insulin resistance and \u03b2-cell dysfunction","volume":"18","author":"Armato","year":"2012","journal-title":"Endocr Pract."},{"key":"2021122117213756900_CIT0042","doi-asserted-by":"crossref","article-title":"Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-labeled, parallel-group controlled study","author":"Tao","DOI":"10.1210\/clinem\/dgaa692"},{"issue":"11","key":"2021122117213756900_CIT0043","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study","volume":"3","author":"Diabetes Prevention Program Research Group","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2021122117213756900_CIT0044","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.amepre.2018.04.038","article-title":"Review of metformin use for Type 2 diabetes prevention","volume":"55","author":"Moin","year":"2018","journal-title":"Am J Prev Med."},{"issue":"6","key":"2021122117213756900_CIT0045","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care."},{"issue":"10077","key":"2021122117213756900_CIT0046","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet."},{"issue":"9323","key":"2021122117213756900_CIT0047","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet."},{"issue":"9541","key":"2021122117213756900_CIT0048","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","author":"Gerstein","year":"2006","journal-title":"Lancet."},{"issue":"12","key":"2021122117213756900_CIT0049","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med."},{"issue":"4","key":"2021122117213756900_CIT0050","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care."},{"issue":"4","key":"2021122117213756900_CIT0051","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2337\/dc18-1970","article-title":"Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the diabetes prevention program and diabetes prevention program outcomes study","volume":"42","author":"Diabetes Prevention Program Research Group","year":"2019","journal-title":"Diabetes Care."},{"key":"2021122117213756900_CIT0052","doi-asserted-by":"crossref","first-page":"S913","DOI":"10.1016\/j.dsx.2017.07.015","article-title":"Prevention of type 2 diabetes mellitus in polycystic ovary syndrome: a review","volume":"11","author":"Anwar","year":"2017","journal-title":"Diabetes Metab Syndr."},{"issue":"2","key":"2021122117213756900_CIT0053","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4093\/dmj.2016.40.2.99","article-title":"An update on the effect of incretin-based therapies on \u03b2-cell function and mass","volume":"40","author":"Chon","year":"2016","journal-title":"Diabetes Metab J."},{"issue":"1","key":"2021122117213756900_CIT0054","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia."},{"issue":"7","key":"2021122117213756900_CIT0055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/00365529609009147","article-title":"Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day","volume":"31","author":"Orskov","year":"1996","journal-title":"Scand J Gastroenterol."},{"issue":"9","key":"2021122117213756900_CIT0056","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1210\/me.2014-1335","article-title":"Induction of miR-132 and miR-212 Expression by glucagon-like peptide 1 (GLP-1) in rodent and human pancreatic \u03b2-cells","volume":"29","author":"Shang","year":"2015","journal-title":"Mol Endocrinol."},{"issue":"1","key":"2021122117213756900_CIT0057","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3892\/ijmm.2015.2207","article-title":"Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets","volume":"36","author":"Huang","year":"2015","journal-title":"Int J Mol Med."},{"issue":"5","key":"2021122117213756900_CIT0058","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cmet.2014.03.010","article-title":"Pancreatic \u03b2 cell dedifferentiation in diabetes and redifferentiation following insulin therapy","volume":"19","author":"Wang","year":"2014","journal-title":"Cell Metab."},{"issue":"5","key":"2021122117213756900_CIT0059","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","article-title":"GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress","volume":"4","author":"Yusta","year":"2006","journal-title":"Cell Metab."},{"issue":"3","key":"2021122117213756900_CIT0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/09513590.2014.975686","article-title":"Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats","volume":"31","author":"Artunc-Ulkumen","year":"2015","journal-title":"Gynecol Endocrinol."},{"issue":"4","key":"2021122117213756900_CIT0061","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/humupd\/dmz019","article-title":"The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective","volume":"25","author":"Jensterle","year":"2019","journal-title":"Hum Reprod Update."},{"issue":"9","key":"2021122117213756900_CIT0062","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with Type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med."},{"issue":"6","key":"2021122117213756900_CIT0063","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1210\/er.2016-1078","article-title":"Vascular biology of glucagon receptor superfamily peptides: mechanistic and clinical relevance","volume":"37","author":"Pujadas","year":"2016","journal-title":"Endocr Rev."},{"issue":"2","key":"2021122117213756900_CIT0064","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1210\/endo.141.2.7326","article-title":"Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling","volume":"141","author":"MacLusky","year":"2000","journal-title":"Endocrinology."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa692\/33803948\/dgaa692.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/3\/e1420\/41831500\/dgaa692.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/3\/e1420\/41831500\/dgaa692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T17:31:07Z","timestamp":1640107867000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/3\/e1420\/5913018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":64,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9,29]]},"published-print":{"date-parts":[[2021,3,8]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa692","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,9,29]]}}}